8-K: Evoke Pharma Presents Positive Data on GIMOTI for Diabetic Gastroparesis Patients Using GLP-1 Agonists

Evoke Pharma announced study results showing GIMOTI nasal spray significantly reduced healthcare resource utilization in diabetic gastroparesis patients also using GLP-1 agonists compared to oral metoclopramide.

Summary

• Evoke Pharma presented data at the American College of Gastroenterology (ACG) 2024 Annual Meeting regarding the use of GIMOTI (metoclopramide nasal spray) in diabetic gastroparesis (DGP) patients who are also using glucagon-like peptide-1 (GLP-1) receptor agonists.
• The study compared GIMOTI to oral metoclopramide (OMCP) in patients with a prior GLP-1 prescription, focusing on healthcare resource utilization (HRU).
• The study included 92 patients, with 51 in the nasal metoclopramide (NMCP) group and 41 in the oral metoclopramide (OMCP) group.
• Patients using GIMOTI experienced a 55% reduction in all-cause emergency department visits and a 28% reduction in DGP-related emergency department visits compared to their pre-treatment levels.
• Compared to oral metoclopramide, GIMOTI resulted in a 91% reduction in all-cause emergency department visits and an 89% reduction in DGP-related emergency department visits.
• GIMOTI also showed a 41% reduction in all-cause office visits and a 66% reduction in DGP-related office visits compared to oral metoclopramide.
• A separate safety analysis of 36 women using GLP-1 drugs during a 28-day study showed no serious adverse events and a trend toward nausea improvement with GIMOTI.

Sentiment

Score: 8

Explanation: The document presents positive clinical data for GIMOTI, showing significant reductions in healthcare resource utilization. While there are risks mentioned, the overall tone is optimistic about the potential of GIMOTI.

Positives

• The study provides evidence that GIMOTI can effectively treat gastroparesis in patients using GLP-1 agonists.
• GIMOTI use is associated with a significant reduction in costly healthcare visits, including emergency room and office visits.
• The safety analysis showed no serious adverse events, suggesting GIMOTI is safe for use in this patient population.
• The results suggest that GIMOTI could be a valuable treatment option for patients experiencing gastroparesis due to GLP-1 medications.

Negatives

• The study was a retrospective analysis, which may have limitations compared to a prospective study.
• The sample size of the study was relatively small, with 92 patients in the main study and 36 in the safety analysis.
• The study results may not be generalizable to all patients with diabetic gastroparesis using GLP-1 agonists.

Risks

• Evoke and EVERSANA may not be able to successfully drive market demand for GIMOTI.
• Market research studies may not accurately predict acceptance by patients, healthcare providers, or payors.
• GLP-1 agonists may not increase the number of patients diagnosed with gastroparesis.
• Alternative treatments for gastroparesis may be developed or approved and may be superior to GIMOTI.
• Evoke's ability to obtain additional financing is uncertain.
• Evoke is entirely dependent on the success of GIMOTI.
• Inadequate efficacy or unexpected adverse side effects relating to GIMOTI could result in recalls or product liability claims.
• Evoke's ability to maintain intellectual property protection for GIMOTI is a risk.

Future Outlook

The company believes GIMOTI has the potential to reduce healthcare resource utilization in diabetic gastroparesis patients taking GLP-1 therapies and that increased use of GLP-1 agonists could increase the patient base for GIMOTI. Evoke also believes GIMOTI can improve treatment of gastroparesis in patients taking GLP-1 agonists.

Management Comments

• Evoke believes GIMOTI can improve treatment of gastroparesis in patients taking GLP-1 agonists.

Industry Context

The increasing use of GLP-1 agonists for type 2 diabetes and weight loss has led to a rise in reports of gastrointestinal side effects, including gastroparesis. This study highlights the potential of GIMOTI to address this growing need, positioning it as a relevant treatment option in the current pharmaceutical landscape.

Comparison to Industry Standards

• The study's findings are significant as they demonstrate a clear benefit of GIMOTI over oral metoclopramide, a commonly used treatment for gastroparesis.
• While direct comparisons to other novel gastroparesis treatments are not provided in this document, the reduction in healthcare resource utilization is a key metric that is often used to evaluate the effectiveness of such treatments.
• The study's focus on patients using GLP-1 agonists is particularly relevant given the increasing prevalence of these medications and their association with gastrointestinal side effects.
• Further studies comparing GIMOTI to other emerging therapies for gastroparesis would be beneficial to fully assess its position in the market.

Stakeholder Impact

• Shareholders may view the positive study results favorably, potentially increasing the company's stock value.
• Patients with diabetic gastroparesis using GLP-1 agonists may benefit from the availability of GIMOTI as a treatment option.
• Healthcare providers may be more likely to prescribe GIMOTI based on the study's findings.
• Payors may be interested in GIMOTI due to its potential to reduce healthcare costs.

Key Dates

Keywords

GIMOTI, metoclopramide, diabetic gastroparesis, GLP-1 agonists, healthcare resource utilization, nasal spray, gastroparesis, Evoke Pharma